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Abstract
Background:  This paper assess the relationship between the quantity of three anti-seizure
medications in hair and the color of the analyzed hair, while controlling for the effects of dose, dose
duration, and patient age for 140 clinical patients undergoing anti-seizure therapy. Three drugs are
assessed: carbamazepine (40 patients), valproic acid (40 patients), and phenytoin (60 patients). The
relationship between hair assay results, hair color, dose, dose duration, and age is modeled using
an analysis of covariance. The covariance model posits the hair assay results as the dependent
variable, the hair color as the qualitative categorical independent variable, and dose, dose duration,
and age as covariates. The null hypothesis assessed is that there is a no relationship between hair
color and the quantity of analyte determined by hair assay such that darker colored hair will
demonstrate higher concentrations of analyte than lighter colored hair.
Results:   T h e  a n a l y s i s  r e v e a l s  t h a t  t h e r e  i s  a  s i g n i f i c a n t  r e l a t i o n s h i p  b e t w e e n  d o s e  a n d
concentration for all hair color categories independent of the other covariates or the categorical
independent variable.
Conclusion:  There does not appear to be any relationship between carbamazepine concentration
and hair color. There is a weak relationship between hair color and valproic acid concentration,
which the data suggest may be mediated by age. There is a significant, moderate relationship
between  phenytoin  concentration  and  hair  color  such  that  darker  colored  hair  has  greater
concentration values than lighter colored hair.
Background
The use of hair assays in order to assess the presence of
ingested chemical materials has been used in a wide va-
riety of applications [1,2]. Hair has been utilized, for ex-
ample, in determining the degree of exposure to heavy
metals in both post mortem and living subjects [3]. In re-
cent years there has been considerable focus on the re-
covery of illicit psychoactive substances and their
metabolites from hair [4,5,6]. Others have reported on a
wide variety of substances that can be recovered from
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human hair samples and can be quantitatively deter-
mined. These include nicotine and cotinine [7], caffeine
[8], antipsychotics and anti-anxiety medications
[9,10,11,12], various antibiotics [13,14,15,16], pesticides
[17], digoxin [18], and steroids [19,20]. There are several
advantages to hair as a sample for analysis, but the single
most important attribute is undoubtedly the long retro-
spective time frame to which analysis of a segment of
hair corresponds. This permits an evaluation of a history
of exposure that is not possible with specimens such as
saliva or urine. A three-centimeter length of hair corre-
sponds, on average, to approximately 90 days of past
time or "history". For compounds that are stable when
sequestered in hair this represents a very desirable prop-
erty.
This enhanced temporal capacity lends itself to the pos-
sibility that hair analysis can be utilized to evaluate indi-
vidual compliance for substances that are taken on a
regular basis, such as anti-clotting medications, antibiot-
ics, and anti-epileptic drugs. This can be an important di-
agnostic and assessment aid in medical practice and
clinical evaluation of drug efficacy. Williams, for exam-
ple, has advocated the use of hair analysis as a method
for assessing therapeutic compliance to anti-seizure drug
regimens [21]. It has been well demonstrated that the
major antiepileptic medications, phenytoin (PHT), car-
bamazepine (CBZ), and valproic acid (VPA) are readily
recovered and quantified from hair specimens [[22–
29]]. Thus, assessing the presence and quantity of these
substances in hair may be a reliable marker for con-
sumption, and provide an additional source of informa-
tion to the physician who has historically relied only on
the patient's self-reported compliance.
Whether hair analysis can be an effective indication of
patient compliance is controversial, however. It is widely
accepted that the qualitative presence of these com-
pounds can be reliably demonstrated by hair analysis.
The controversial aspect is primarily based on the issue
of whether the quantitative value of the assay can be a re-
liable indicator of dose. That is, is there a reliable dose/
assay correlation? Tracqui et al. [30], for example, have
argued that hair analysis has value for qualitative evalu-
ation of drug use, but is "worthless" for quantitative as-
sessment of patient compliance. Williams (1999),
however, argues the opposite, and presents data for a
controlled inpatient population taking CBZ which shows
remarkably good consistency between dose and assay
outcome. Furthermore, Williams suggests that compli-
ance is best measured by using patients as their own con-
trol. This is done by comparing any given assay outcome
to a ground state value. So hair will show a relative
change in concentration. It is generally accepted that
specific quantitative values related to a specific dose can
not applied across study subjects due to substantive indi-
vidual biovariability.
One issue that is not clearly understood is the variety of
factors influencing the considerable biovariability that
appears between persons given identical dosages of these
drugs. Clinicians general recognize that a very large
number of factors can influence the drug concentration
in any analytic matrix. One potential advantage of hair
specimens is they may represent a relatively stable ma-
trix over a relatively long time frame. Tracqui, even in re-
jecting the utility of quantitative compliance monitoring
in this context, notes that a number of studies reported
significant strong correlation between dose and assay
outcomes for a number of different compounds, with
Pearson's r ranging from .772 to .868. Another aspect of
this interpretation controversy concerns whether there
are systematic influences on drug concentration in hair
because of color variations, differences in cosmetic treat-
ment, and different intensities of hair hygiene. Another
part of the controversy is problems related to the de-
pendency on the accuracy self-reported patient compli-
ance (which may or may not be accurate), and - in the
case of illicit drugs - the purity and actual contents of
drugs reported as consumed. The attending physicians
for these patients were queried on the confidence they
had on their patient's compliance, and in general they
rated the compliance as good, with only a small number
of missed doses. However, we recognize that there are re-
liable data to indicate that patient compliance to anti-sei-
zure medication regimens may be weak, and a
delimitation of this research is that there was not rigid
control of patient compliance.
One of the general weaknesses characterizing much of
the analysis of hair assay data has been the inadequacy of
the statistical models used to assess the experimental in-
formation. Oftentimes claims or conclusions are derived
from experimental data that is not supported by statisti-
cal analysis. In some cases, in fact, analyses of the data
show that the conclusions reached are clearly incorrect
[31]. There has been, in general, a failure in the assess-
ment of experimental hair analysis data to use appropri-
ate available statistical procedures, or to assess whether
the critical assumptions that underlay statistical proce-
dures are met by the data. And almost without exception,
there has been no utilization of more sophisticated and
sensitive statistical techniques that are available to ex-
amine multivariate phenomena. This is true even though
there is a general recognition that the relationship be-
tween dose and assay are likely to mediated by a complex
series of intervening events and are particularly appro-
priate to this analytic approach.BMC Clinical Pharmacology (2001) 1:2 http://www.biomedcentral.com/1472-6904/1/2
Materials and Methods
The analysis is based upon the concentrations obtained
from scalp hair collected by cutting hair from the poste-
rior vertex of the head. Each sample consisted of approx-
imately 200 mg of hair. Each sample was sectioned into
2-cm segments and each segment was analyzed by FPIA
and HPLC methods for CBZ and PHT and by FPIA for
VPA. The number of segments for each patient varied,
since it was dependent of length of hair available from
each individual. Most patients have five segments and no
patient provided less than two segments. The concentra-
tions used for each case are the mean values for all avail-
able segments for that patient. HPLC values are used in
the analysis of CBZ and PHT, FPIA values are used in the
analysis of VPA. As well, serum assay values are provided
for each patient. The serum assay typology varied, in-
cluding multiple methods to assay serum for some drugs.
For CBZ serum was assayed by both FPIA and GC/MS,
for VPA by FPIA, and for PHT by FPIA and HPLC. Bloods
were drawn from patients in the morning by their at-
tending physician. In a few cases there were multiple
bloods drawn. In such cases the mean values for the se-
rum levels are represented in the tables. Hair color as-
signments were based upon observation by the attending
physician, questioning of the patient and in cases of am-
biguity by consultation among the field research staff,
the attending physician, and the patient.
Since this is a secondary analysis of data, only a synopsis
of technical procedures is presented here. Details of the
instrumentation, including calibration and standardiza-
tion, and elaboration of the analysis techniques are de-
scribed in detail elsewhere [28] and are not repeated
here. The general approach was as follows: hair samples
were dissolved in a strong base (NaOH) and the dis-
solved material was subjected to solvent extraction. Hair
samples were segmented in 2-cm sections, and 30-50 mg
of hair from each segment was added to 3 ml of 1 N
NaOH solution. The solution was solvent extracted with
diethyl ether, centrifuged, and the supernatant evaporat-
ed. The remnant residue was dissolved in saline and sub-
jected to analysis.
Result and Discussion
In this study we report on the relation between the con-
centration of three widely used anti-epileptic medica-
tions, CBZ, PHT, and VPA, in hair and the correlation
between dose and concentration. In addition, we explore
the relationship between concentration and hair color,
between assay variability and age, and the interaction ef-
fects between these variables. We also assess the degree
to which the data meet critical assumptions regarding
the normality, distribution shape, and variance homoge-
neity. The statistical method employed is an analysis of
covariance, in which each drug employs a model incor-
porating the concentration of the target drug in hair as
the dependent variable, the hair color categorization as
the independent variable, and dosage, duration of dose,
and age as model covariates.
Carbamazepine (CBZ)
The data set consists of 40 subjects (18 females, 22
males) who were on a regimen of CBZ for the control of
seizures. The mean of age of this group is 30.3 years, s.d.
18.6 (median 25.0). Age skewness (.651) and kurtosis (-
.506) are within normal bounds. The mean length of
time (duration) of the dose regimen for this group was
16.95 months (s.d. 8.59) with a range of from 2 to 24
months. The dosage values (in mg/day) ranged from 200
to 1,000 with a mean dose of 525 mg/day (s.d. 208.47,
median 450). For both duration of regimen and daily
dosage the skewness and kurtosis values are within nor-
mal range (<2).
Table 1: Mean Concentration Values and Correlation Coefficients for Dose/Assay Relationship for Hair and Plasma, CBZ
CBZ HPLC Hair Correlation FPIA Correlation
Specimen Dose Concentration S.D. Coefficient Concentration S.D. Coefficient
(mg/day) (mcg/g) (r) (mcg/g) (r)
Hair 525 18.20 6.02 0.476** 21.12 7.01 0.459**
CBZ GC Serum Correlation FPIA Serum Correlation
Specimen Dose Concentration S.D. Coefficient Concentration S.D. Coefficient
(mg/day) (mcg/g) (r) (mcg/g) (r)
Serum 525 7.37 1.44 .067 7.62 1.50 .143
** significant @.01, two-tailedBMC Clinical Pharmacology (2001) 1:2 http://www.biomedcentral.com/1472-6904/1/2
General Dose/Assay Relationship
The data for the dose assay relationship includes concen-
tration in the plasma serum, which was determined by
both FPIA and GC, and concentration in the hair, which
was determined by both FPIA and HPLC. For hair assays
the values are in micrograms per gram of hair, and for se-
rum the values are in micrograms per milliliter of plas-
ma. The findings show that there was no significant
dose/assay relationship for the serum specimens with ei-
ther analytic technique, and that there was a significant
dose/assay relationship for hair specimens by both ana-
lytic techniques. The results are shown in Table 1.
Hair Color
It has been a source of controversy in the interpretation
of hair assays whether or not hair color is a critical factor
in the binding of materials in hair. It has previously re-
ported that CBZ does not appear to have a significant
"color effect" (i.e., that darker hair shows significantly
higher concentrations of CBZ than light hair) [31]. We
examine this finding using the current data. There are
five color categorizations of hair represented among the
40 subjects. The distribution of hair color and the mean
concentration of CBZ for each color are shown in Table 2.
The concentration values are in micrograms/gram as
measured by HPLC.
An analysis of variance for this table fails to show a sig-
nificant relationship between CBZ mean value and hair
color (F = 1.374, p= .263). The Levene Test for equality of
error variances indicates that the homogeneity of vari-
ance assumption is met (Levene F = .303, p = .874). The
K-S and Shapiro-Wilk tests for normality are consistent
with a normal distribution and a normal Q-Q plot of CBZ
concentration in hair shows a good approximation of
normality.
Hair Color/Dose Relationship
Another factor worth consideration is the possible inter-
action effect between hair color and dose. The dose val-
ues and hair color categories can be a shown as a matrix
array as in Table 3.
Table 3 is a crosstabulation showing the distribution of
dosage values by hair color. Review of the cell distribu-
tions shows a concentration of higher dose regimens to
cluster towards the lower left, indicating the possibility
that persons with black hair may more likely to be on
higher doses of CBZ and persons with lighter hair may be
more likely to receive lower doses. The GLM covariance
model is based on the mean hair assay outcomes
(HPLC). The analysis of covariance (ANCOVA) allows for
the comparison of quantitative dependent and qualita-
tive independent variable while simultaneously control-
ling for a number of quantitative variables or covariates.
In this analysis, the dependent variable is the mean con-
centration for the hair analysis, the independent qualita-
tive variable is the hair color categorization, and the
covariates are duration of dose (in months), dose (in
mgs. per 24 hours), and patient age (in years). The out-
come of this model is shown in Table 4.
Table 4 reveals that there is a relation between mean hair
concentration and dose (F = 5.020, p = .032, eta2 = .136,
shaded row) while the relationship between hair assay
result and color is not significant (F = .682, p = .609, eta2
= .079). Thus it is reasonable to conclude that differen-
tial hair assay outcomes for CBZ are not color dependent,
but are significantly related to dose regimens.
Table 2: Mean Concentration of CBZ by Hair Color
Hair Color Number of Mean CBZ Standard
Subjects Concentration Deviation
Black 15 17.59 5.95
Brown 15 18.05 5.74
Blond 3 24.23 6.22
Gray 3 13.58 3.27
Dyed 4 19.97 7.39
Overall Mean 40 18.20 6.02





Blond Gray Dyed Total
(mg/day)
200 2 1 3
300 1 1 2
400 5 9 1 15
500 1 1 2
600 7 1 2 1 11
800 1 2 1 4
1000 1 2 3
T o t a l1 5 1 5 334 4 0BMC Clinical Pharmacology (2001) 1:2 http://www.biomedcentral.com/1472-6904/1/2
Valproic Acid (VPA)
The VPA data set consists of 40 subjects (25 females, 15
males) who were on a regimen of VPA for the control of
seizures. The mean of age of this group is 23.25 years,
s.d. 19.15 (median 18.0). Age skewness is 1.73 and kurto-
sis is 3.35. The skewness is somewhat outside of normal
bounds (ratio 4.6), the kurtosis (ratio 4.5) indicates a
peaked distribution. Neither ratio is, however, extreme.
The mean length of time (duration) of the dose regimen
for this group was 16.275 months (s.d. 8.51) with a range
of 23 months. The dosage values (in mg/day) ranged
from 200 to 3000 mg/day with a mean dose of 822.5
mg/day (s.d. 558.6, median 600). For both duration of
regimen and daily dosage the skewness and kurtosis val-
ues are within normal range (<2).
General Dose/Assay Relationship
The data for the VPA dose assay relationship includes
concentration in the plasma serum, which was deter-
mined by FPIA, and concentration in the hair, which was
determined by FPIA. For hair assays the values are in mi-
crograms per gram of hair, and for serum the values are
in micrograms per milliliter of plasma. The findings
show that there was no significant dose/assay relation-
Table 4: General Linear Model, Analysis of Covariance, Hair Assay Outcome by Color, Dose, Dose Duration, and Age, CBZ
Source Type III Sum of Squares df Mean Square F Sig. Eta2
Corrected Model 428.88 7 61.27 1.995 .087 .304
Intercept 346.37 1 346.37 11.281 .002 .261
CBZDOSE 154.13 1 346.37 11.281 .002 .136
DOSEDUR 2.89 1 2.89 .094 .761 .003
AGE .636 1 .636 .021 .886 .001
COLOR 83.78 4 20.95 .682 .609 .079
Error 982.57 32 30.71
Total 14658.77 40
Corrected Total 1411.45 39
Table 5: Mean Concentration Values and Correlation Coefficients for Dose/Assay Relationship for Hair and Plasma, VPA
VPA Mean FPIA Mean Correlation
Specimen Dose Concentration S.D. Coefficient
(mg/day) (mcg/g) (r)
Hair 822.5 8.22 3.37 .717**
VPA FPIA Mean Correlation
Specimen Mean Concentration S.D. Coefficient
Dose (mcg/ml) (r)
(mg/day)
Serum 822.5 60.8 20.74 .128
** significant @.01, two-tailedBMC Clinical Pharmacology (2001) 1:2 http://www.biomedcentral.com/1472-6904/1/2
ship for the VPA serum specimens, and that there was a
significant correlation dose/assay relationship for VPA
hair specimens. The results are shown in Table 5.
Hair Color
As with CBZ, we will examine the potential for a "color ef-
fect" associated with the reported concentrations of re-
covered VPA. The color categorizations are identical to
those used for CBZ. Table 6 reports the mean concentra-
tion of VPA by hair color category. There are no dyed
specimens so four color categories are used in this anal-
ysis.
An analysis of variance for Table 6 fails to show a signif-
icant relationship between VPA mean values and hair
color (F = 2.354, p = .088). The Levene Test for equality
of error variances indicates that the homogeneity of var-
iances assumptions is met (Levene F = 2.491, p = .076).
The K-S test for normality is consistent with a normal
distribution and a normal Q-Q plot of VPA concentration
in hair shows a good approximation of normality.
Hair Color Relationship
As with CBZ, we now consider the possible interaction of
hair color, dose, and recovered VPA from hair. Table 7
presents the frequency distribution of dose by hair color.
Visual inspection of the Table 7 is consistent with the im-
pression that there may be a slight skewing of higher dos-
age regimens towards dark-haired subjects. We subject
this data to an ANCOVA. As previously, we treat mean
concentration as the dependent term, color as the inde-
pendent qualitative term, and dose duration, 24-hour
dose value and age as the covariates. The outcome for
this model is reported in Table 8. The Levene statistic
shows the variance homogeneity criteria are met, and
analysis of the normality of the distribution of the mean
hair values shows acceptable conformity with normality
assumptions.
Table 8 demonstrates that the relationships between
dose, age, and hair color are all significant (shaded
rows), while duration of dose regimen is not. Further-
more the eta2 values, which are interpretable as a meas-
ure of the percentage of the explainable variance, show
similar contributions between color and dose, and a less-
er contribution due to age. Table 9 reports these con-
trasts using Bonferroni's criteria.
The Bonferroni criteria contrasts indicate that specific
pair comparisons do not yield a significant difference, al-
though the contrasts for black/gray and black/blond are
approaching significance. Doing the pairs comparisons
using Sidak criteria yields the same results. Both of these
confidence interval criteria are conservative but the Bon-
ferroni criteria are preferred on the basis that there is a
relatively small number of comparison pairs.
An additional issue of importance is the potential com-
plex interaction between dose, age, and color categoriza-
tion. First, the data demonstrate a difference in mean
dose value by age, although those differences are not sig-
nificant for VPA (the correlation for dose and age is r =
.265, p = .098). Furthermore, the covariance model can
be used to generate model regression-derived mean esti-
mates (adjusted for age and dose) that can be compared
to the observed values. Both the analytic values and the
estimated values are shown in Table 10.
Table 6: Mean Concentration of VPA by Hair Color




Black 17 9.65 3.39
Brown 17 7.58 3.30
Blond 3 5.80 1.36
Gray 3 6.08 2.12
Overall Mean 40 8.22 3.37
Table 7: Frequency Distribution of VPA Dosage by Hair Color
VPA Dose Hair Color
(mg/day)
Black Brown Blond Gray Total
200 1 1
300 2 3 1 6
400 1 3 1 5
500 3 3




1000 1 3 1 5
1500 7 1 8
3000 1 1
Total 17 17 3 3 40BMC Clinical Pharmacology (2001) 1:2 http://www.biomedcentral.com/1472-6904/1/2
Comparison of the observed mean values and the model-
estimated mean values shows that the model is relatively
efficient for all color categorizations except gray hair,
where the observed values are nearly twice the value of
the estimated values. Since age and gray hair are colline-
ar in the data set Table 10, it is possible that the age/color
account for this departure. Regression evaluation of the
color/age collinearity for either dose or mean concentra-
tion is consistent with this effect (eigenvalue, age = .228,
eigenvalue, color = .081). Small eigenvalues are consist-
ent with collinearity between the covariate factors, and
thus these values are indicative of an age/color collinear
condition.
To further examine this effect, we produce a final covar-
iance model for VPA with color categorization as the in-
dependent factor and dose as the covariate. The results
of this model are presented in Table 11.
The 2-factor model (dose and color) presented in Table
11 are consistent with the conjecture that age and color
demonstrate some interactive or synergistic effect, since
color alone fails to attain significance.
Table 8: General Linear Model, Analysis of Covariance, Hair Assay Outcome by Color, Dose, Dose Duration, and Age, VPA.
Source Type III Sum of Squares df Mean Square F Sig. Eta2
Corrected Model 299.12 6 49.85 11.38 .000 .674
Intercept 10.52 1 10.52 2.40 .131 .068
VPADOSE 61.03 1 61.03 13.93 .001 .297
DOSEDUR 11.55 1 11.55 2.64 .114 .074
AGE 23.35 1 23.35 5.33 .027 .139
COLOR 51.16 3 17.05 3.892 .017 .264
Error 144.59 33 4.38
Total 3143.34 40
Corrected Total 443.71 39
Table 9: Pairwise Comparisons, Hair Color Categories by Mean VPA Concentration
Hair Color Hair Color Mean Difference Std. Error Sig.a
(I) (J) (I-J)
Black Brown 1.811 .758 .135
Blond 3.584 1.368 .078
Gray 6.457 2.344 .056
Brown Black -1.811 .759 .135
Blond 1.772 1.345 1.000
Gray 4.646 2.209 .258
Blond Black -3.584 1.368 .078
Brown -1.772 1.345 1.000
Gray 2.873 2.422 1.000
Gray Black -6.457 2.344 .056
Brown -4.646 2.209 .258
Blond -2.873 2.422 1.000
a Bonferroni adjustment for multiple comparisonsBMC Clinical Pharmacology (2001) 1:2 http://www.biomedcentral.com/1472-6904/1/2
It is reasonable to surmise that the color effect for VPA is,
at best, weak and mostly likely collinear with age. How-
ever, there is an effect for color that is operating as a
stronger effect than discerned in the analysis of CBZ.
This effect appears to be dependent on the stringency of
the significance criteria used in the analysis, and the de-
gree to which the analytic model disaggregates the hy-
pothesized variable relationships. Selecting less
conservative criteria will produce a weak, generalized
significant color/assay relationship, but application of
either more conservative methods to assess pair-rela-
tionships (e.g. Bonferroni criteria), or use of more elabo-
rate model specifications (e.g., step-wise ANCOVA) fail
to sustain significance. One of the more serious con-
straints on the VPA analysis presented here is the very
limited number of persons with gray hair, and the
number of light-haired persons in general (only 6 of the
40 subjects were not classified as either black or brown
hair). A more confident analysis would require a sample
with larger numbers
Phenytoin (PHT)
The PHT data set consists of 60 subjects (26 females, 34
males). The mean of age of this group is 35.85 years, s.d.
16.45 (median 35.0). Age skewness (.197) and kurtosis (-
.844) are within normal bounds (skewness ratio = 0.64,
kurtosis ratio = -.844). The mean length of time (dura-
tion) of the dose regimen for this group was 16.52
months (s.d. 8.88) with a range of from 2 to 24 months.
The dosage values (in mg/day) ranged from 100 to 400
with a mean dose of 243.3 mg/day (s.d. 103.12, median
250). For both duration of regimen and daily dosage the
skewness and kurtosis values are within normal range
(<2).
General Dose/Assay Relationship
The data for the dose assay relationship includes concen-
tration in the plasma serum, which was determined by
HPLC, and concentration in the hair, which was deter-
mined by both FPIA and HPLC. For hair assays the val-
ues are in micrograms per gram of hair, and for serum
the values are in micrograms per milliliter of plasma.
We note that, in contrast to both CBZ and VPA, Table 12
reveals that there is a significant bivariate dose/assay
correlation for the serum specimens, and for the hair
specimens by both analytic techniques.
Table 10: Mean Concentration Values and Model-Estimated 
Mean Values, VPA
Hair Color Mean Estimated Means1,
(N) Concentration VPA (S.E.)
VPA (S.D.)
Black (17) 9.65 (3.39) 9.74 (.572)
Brown (17) 7.58 (3.30) 7.93 (.525)
Blond (3) 5.81 (1.36) 6.15 (1.24)
Gray (3) 6.08 (2.12) 3.64 (2.09)
1Evaluated at model covariates: VPA dose (mg/24hr) = 822.5, Age = 
23.25
Table 11: General Linear Model, Analysis of Covariance, Hair Assay Outcome by Color and Dose VPA
Source Type III Sum fo Squares df Mean Square F Sig. Eta2
Corrected Model 263.71 4 65.928 12.82 .000 .594
Intercept 185.62 1 185.62 36.09 .000 .508
VPADOSE 190.93 1 190.93 37.13 .000 .515
COLOR 35.61 3 11.87 2.31 .093 .165
Error 179.99 35 5.14
Total 3143.34 40
Corrected Total 443.71 39BMC Clinical Pharmacology (2001) 1:2 http://www.biomedcentral.com/1472-6904/1/2
Hair Color
Table 13 reports the number of subjects for each of four
hair color categorizations, the mean concentration of
PHT for that color category, and the related standard de-
viation. Visual examination of the table shows that both
black and brown color had notably higher concentrations
than either blond-haired or gray-haired subjects.
A univariate ANOVA on the data in Table 13 reveal that
there is a significant difference by hair color (F = 10.2, p
= .000). However, the Levene Test indicates that the ho-
mogeneity of variance assumption is not met. An alter-
native analysis using Tamhane's procedure, allowing an
assessment of unequal variances comparisons, also indi-
cates significance, but allows for post-hoc contrasts for
each specific color group. The individual comparisons
are shown in Table 14.
Table 12: Mean Concentration Values and Correlation Coefficients for Dose/Assay Relationship for Hair and Plasma, PHT
Specimen PHT HPLC Hair PHT Correlation FPIA Hair Mean Correlation
Mean Mean Coefficient PHT Concentration Coefficient
Dose Concentration (r) [sd] (mcg/g) (r)
(mg/day) [sd] (mcg/g)
Hair 243.3 13.71 [7.32] .882** 13.67 [7.20] .883**
Specimen PHT HPLC Serum Correlation FPIA Serum Mean Correlation
Mean Mean PHT Coefficient PHT Concentration Coefficient
Dose Concentration (r) [sd] (mcg/ml) (r)
(mg/day) [sd] (mcg/ml)
Serum 243.3 14.00 [3.40] .779** 14.2 [3.50] .743**
** significant @.01, two-tailed
Table 13: Mean Concentration of PHT by Hair Color
Hair Color Number of Mean PHT Standard
Subjects Concentration Deviation
Black 24 16.35 5.79
Brown 18 16.76 7.68
Blond 8 7.92 2.92
Gray 10 6.55 4.82
Overall Mean 60 13.71 7.32
Table 14: Tamhane Post-Hoc Comparison of Color Groupings, 
PHT








Table 15: Frequency Distribution of PHT Dosage by Hair Color
PHT Dose Hair Color
(mg/day)
Black Brown Blond Gray
100 4 2 2 6
200 4 6 4 2
300 12 4 2 2
400 4 6 0 0
Total 24 18 8 10BMC Clinical Pharmacology (2001) 1:2 http://www.biomedcentral.com/1472-6904/1/2
The ANOVA indicates that that there are significant dif-
ferences in concentration of PHT by hair color. The over-
all mean concentration values appear to cluster, with the
black/brown hair contrast showing no significant differ-
ence, and blond/gray contrast showing no significant
difference. However, contrast of either blond or gray hair
to black or brown hair does show significant difference.
The overall distribution of PHT in the hair assays ap-
pears to meet the normality assumptions well.
Hair Color/Dose Relationship
In order to further assess the nature of the hypothesized
color effect, it is important to assess whether or not there
is an interaction effect of color and dose. Is the effect a re-
sult of dosing values are higher for dark-haired subjects?
Table 15 reports the relative frequency of daily dose reg-
imens by hair color group.
Table 15 indicates that the higher dose values appear to
cluster to some degree with black and brown-haired sub-
jects. In order to assess this an ANCOVA model including
dose, dose duration, age, and hair color is assessed. Re-
sults of that model are shown in Table 16.
Table 16 indicates that age, dose, and color are signifi-
cant factors in the model (values shaded gray are signifi-
cant) while dose duration is not. This is identical to the
model outcome for VPA. Table 17 shows the Bonferroni
criteria for all pairwise combinations, their means differ-
ences, and their significance outcomes.
As with VPA, the pairwise contrasts show that the black
and gray and brown and gray contrasts are significant,
while the remaining pairs do not have significant mean
differences (the same results is obtained using Sidak cri-
teria). It suggests, as with VPA, that there may be a color/
age/dose confounding action involving either collinear
or confounding relationships between hair color, dose,
and age. In order to assess this we first consider the ob-
served means and the estimates mean values from the
ANCOVA model. This is presented in Table 18.
Table 16: General Linear Model, Analysis of Covariance, Hair Assay Outcome by Dose, Dose Duration, Age, and Hair Color, PHT
Source Type III Sum of Squares df Mean Square F Sig. Eta2
Corrected Model 2750.79 6 458.46 59.70 .000 .871
Intercept 78.61 1 78.61 10.24 .002 .162
AGE 48.64 1 48.64 6.34 .015 .107
DOSE 1593.67 1 1593.67 207.54 .000 .797
DOSEDUR 11.04 1 11.04 1.44 .236 .026
COLOR 227.13 3 75.71 9.86 .000 .358
Error 406.98 53 7.68
Total 14441.1 60
Corrected Total 3157.77 59
Table 17: Pairwise Comparisons, Hair Color and Concentrations, 
PHT
Hair Color Hair Color Mean Std. Sig.a
(I) (J) Difference Error
(I-J)
Black Brown .168 .865 1.000
Blond 3.287 1.245 .065
Gray 5.902* 1.265 .000
Brown Black -.168 .865 1.000
Blond 3.119 1.292 .116
Gray 5.734* 1.327 .000
Blond Black -3.287 1.245 .065
Brown -3.119 1.292 .116
Gray 2.615 1.680 .754
Gray Black -5.902* 1.265 .000
Brown -5.732* 1.327 .000
Blond -2.615 1.680 .754
a Bonferroni adjustment for multiple comparisons * mean difference is 
significant at he .05 levelBMC Clinical Pharmacology (2001) 1:2 http://www.biomedcentral.com/1472-6904/1/2
Table 18 reveals that the model-estimated means for
dark hair (black and brown) are lower than the observed
values, and the estimates for light colored hair are great-
er. This is a departure from the VPA pattern, and is con-
sistent across category with a color/concentration
positive relationship.
We can assess this effect by examining the ANCOVA
model retaining dose and hair color as the sole covariates
(replicating the procedure applied to VPA) and examin-
ing the surviving significant relationship. The results of
this model are shown in Table 19.
Consistent with the approach applied to VPA, we delete
age from the model in Table 19. Age is removed from the
model in this case to see if it diminishes the color effect,
as was the case VPA. Comparison of Tables 17 and 18
show that the eta2 is diminished, but is still significant
and makes a substantial contribution to the explained
variance. Dose still has, however, the higher eta2 value.
Further pairwise comparisons show that there are signif-
icant mean value contrasts between the light hair catego-
ries (gray and blond) and the dark hair categories (black
and brown). There are, however, no significant contrasts
within those groups (i.e., no significant mean differences
between black and brown hair or blond and gray hair).
Conclusions
This assessment of the recovery of three compounds,
CBZ, VPA, and PHT, from hair samples identifies a vari-
able effect of hair color on assay concentration by drug
type. The generalized hypothesis assessed is that darker
coloration of hair is associated with a greater concentra-
tion of analyte in the hair. For CBZ, hair color does not
appear to exert a significant effect on the quantity of the
compound recovered from hair. For VPA there appears
to be a very weak color effect, but the number of light-
haired subjects attenuates the strength of the conclusion.
For all drugs there appears to be a significant positive re-
lationship between dose and hair concentration. We also
suggest that for VPA there appears to be effects of col-
linearity between age and hair color, and possibly dose
and hair color. Both of these phenomena could produce
confounding effects in trying to describe the dose/assay
relationship. The limitations of the data are that the sub-
jects are a clinical, non-random, population and the
range of dosages across all color grouping was not uni-
form, nor was dosage duration. Furthermore, the
number of light hair subjects was, for certain drugs, very
small.
Table 18: Mean Concentration Values and Model-Estimated 
Mean Values, PHT
Hair Color Mean Estimated Means1,
(N) Concentration PHT (S.E.)
PHT (S.D.)
Black (24) 16.35 (5.79) 15.184 (0.58)
Brown (18) 16.76 (7.68) 15.02 (0.67)
Blond (8) 7.91 (2.92) 11.96 (1.11)
Gray (10) 6.55 (4.82) 9.23 (1.09)
1Evaluated at model covariates: PHT dose (mg/24hr) = 243.3, Age = 
35.85
Table 19: General Linear Model, Analysis of Covariance, Hair Assay Outcome by Dose and Hair Color, PHT
Source Type III Sum of Squares df Mean Square F Sig. Eta2
Corrected Model 2648.08 4 662.02 71.44 .000 .839
Intercept 2.25 1 2.25 .243 .624 .004
DOSE 1532.31 1 1532.31 165.35 .000 .750
COLOR 191.68 3 63.89 6.895 .001 .273
Error 509.69 55 9.27
Total 14441.1 60
Corrected Total 3157.77 59BMC Clinical Pharmacology (2001) 1:2 http://www.biomedcentral.com/1472-6904/1/2
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